Novocure (NVCR) announced that the U.S. FDA has approved Optune Pax for adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
Pancreatic cancer remains one of the most lethal malignancies, with limited treatment advances over the past three decades. Optune Pax is a wearable medical device that delivers Tumor treating Fields (TTFeilds), a non-invasive therapy that uses altering electric fields to disrupt cancer cell division while sparing healthy tissue.
The approval was based on the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in overall survival and delayed pain progression compared to chemotherapy alone.
Optune Pax is Novocure's first FDA-approved therapy for pancreatic cancer, marking a milestone for the company's TTFields platform. The device was well tolerated in clinical studies, with the most common adverse events being mild-to-moderate skin reactions under the arrays. No new systemic safety signals were observed.
When we alerted readers to NVCR on Dec.2, 2025, it was trading at $11.82.
NVCR has traded between $9.82 and $22.95 over the past year. The stock closed yesterday's trading at $10.50, up 0.29%, and rose further in the overnight trading to $13.66, up 30.10%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.